New Endometrial Targets Beyond HER2

Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and other emerging targets are generating enthusiasm, particularly because they may broaden treatment options for patients who do not meet narrower biomarker criteria associated with some currently available therapies